Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnlbVU2yqEQvF2= MnS1OFjDqGh? NW\ZZnJx[myxY3vzJFI4NU:KQz3pcoR2[2WmIHPlcIwheHKxbHnm[ZJifGmxbjDjc41x[XKjYnzlJJRwKHSqYYSgc4Yh[mG|YXygcIV3\Wy| Mmj0NlY{PTB3NkW=
NP69 NVXkTGdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPmWolKSzVyPUOxMlY6yrF{LkW0JO69VQ>? M4PH[lI3OjV{NUe1
NP460 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTaTWM2OD1{Mj64OeKyOS5zODFOwG0> NWLhUJJGOjZ{NUK1O|U>
C666-1 NYrUV|l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jvNGlEPTB;MUmuPVXDuThwOUOg{txO MlTFNlYzPTJ3N{W=
C666-1 M2DmXmNmdGxiVnnhZoltcXS7IFHzd4F6 NFr1VXkyOCEEtV2= NE\aWWg1QCCq NHnibY9FVVOR NUPT[3dTe2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gZ4l{eGyjdHnu MVGyOlI2OjV5NR?=
C666-1  NUe0UW5HTnWwY4Tpc44hSXO|YYm= NYrM[W9kOTBiwsXN M4HwWlI1KGh? NHLQfG9FVVOR NYewV4lX[WO2aY\heIV{KHSqZTDwOVMheGG2aIfhfUwhfXC{ZXf1cIF1cW6pIIC1N{wheDJzIHHu[EBO\G1{ MkC3NlYzPTJ3N{W=
C666-1 NF2xfnpCeG:ydH;zbZMhSXO|YYm= NWPBNnpbOTBiwsXN M17HflQ5Nzd{IHi= NEnrNGRFVVOR M{TPVpNmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJINqe3CuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MoC3NlYzPTJ3N{W=
A549 M3nWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmyOEBp MkXNTWM2OD1zNz62PEDDuSB2LkWyJO69VQ>? NGHOWmUzPjF{NUKzNC=>
A549-NTC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnmOlVoOjRiaB?= NHnZbHJKSzVyPUG5MlQzKMLzIEGuPVYh|ryP NUHXPI1POjZzMkWyN|A>
A549-920 M3TON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17mZVI1KGh? NH:5S4VKSzVyPUOzMlg2KMLzIESuPFQh|ryP MXiyOlEzPTJ|MB?=
CRL-5908 NFKyPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LselI1KGh? MkP5TWM2OD1|OD63NUDDuSB{LkSzJO69VQ>? MXiyOlEzPTJ|MB?=
L6 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP3NVDDqM7:TdMg MYOyOE81QC95MjDo M3HzPGROW09? MXzpcohq[mm2czDj[YxteyCycn;sbYZmemG2aX;uJIFv\CCmaX\m[ZJmdnSrYYTpc44> NIjSNpAzPTh5MUe5OC=>
C2C12 NXG0c5VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PuSlExyqEQvF5CpC=> Ml[1NlQwPDhxN{KgbC=> MX3EUXNQ MkfubY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v NXfvPIJHOjV6N{G3PVQ>
MCF-7  M1;0[GZ2dmO2aX;uJGF{e2G7 MUGxNOKh|ryP M{nYemROW09? M3LIVolvcGmkaYTzJIN6[2yrbjDENUBidmRiRHnj[ZLDqA>? MlXBNlU4ODJ5MEO=
DU4475  M3nsOmZ2dmO2aX;uJGF{e2G7 NWfNW4E6PS9zMD:yNEDPxE1? MW[yOOKhcA>? Mmew[I94dnKnZ4XsZZRmeyCWb3PhMVEh\G:|ZTDk[ZBmdmSnboTsfS=> MYSyOVU1PzF5NB?=
SMMC-7721 NH\3eYtHfW6ldHnvckBCe3OjeR?= MWexNEDPxE1? MVm0PEBp NH\GdHBFVVOR MmXwZ4F2e2W|IFTORUBFW0JiZHHtZYdm NIP1WJEzPTV2NEO2NS=>
SMMC-7721 M4PCcWZ2dmO2aX;uJGF{e2G7 M4DQ[lExKM7:TR?= NGPESGk1QCCq NXvBNHU{TE2VTx?= MlThbY5lfWOnczD0bIUh[2i{b33heIlvNWKxdX7kJJBzd3SnaX6gTWZKOTZidH:gdIFzfGmjbHz5JIxw[2GuaYrlJIlvKHSqZTDjfZRweGyjc35CpC=> NUHXSHJiOjV3NESzOlE>
SMMC-7721 NUXjU5RsTnWwY4Tpc44hSXO|YYm= MmGyNVAh|ryP Mn3yOFghcA>? MonnSG1UVw>? MkTVbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:owrDJSm5DOcLibWLORS=> MUeyOVU1PDN4MR?=
SMMC-7721 M3;QemZ2dmO2aX;uJGF{e2G7 M4fzb|ExKM7:TR?= M{T4O|M3KGh? NYL6eXVjTE2VTx?= Ml3mZ4F2e2W|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY> M2TYNlI2PTR2M{[x
MCF-7 M2HDSWZ2dmO2aX;uJGF{e2G7 MVGxNOKh|ryP MYmwMVI1KGh? MXLpcoR2[2W|IIC1N{BidmRicEKxM2NqeDF? NGHufIUzPTR6MkO3Ny=>
OVCAR10 M2\JOWZ2dmO2aX;uJGF{e2G7 MUGxNOKh|ryP M1vpTlIycMLi NG\jRpRFVVOR NIL6OmFqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ M4Hq[FI2PDJ4NUS4
NCI-H23 NV7pSnpFTnWwY4Tpc44hSXO|YYm= NFfNZ5kyOMLizszN MWiyNYjDqA>? NIPFbmpFVVOR M2L5XYlv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> MV[yOVQzPjV2OB?=
A2780 NFXoTm9HfW6ldHnvckBCe3OjeR?= NFzFVFkyOMLizszN MUmyNYjDqA>? M33wdmROW09? NVrLNG9kcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? MU[yOVQzPjV2OB?=
NCI-H23 M3\oZmZ2dmO2aX;uJGF{e2G7 MXqxNOKh|ryP M4LFTVIycMLi NVf0[JdZTE2VTx?= NV3p[Wts\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> NWmzVI5pOjV2Mk[1OFg>
A2780 NUjhSYxOTnWwY4Tpc44hSXO|YYm= MWexNOKh|ryP M3TCeFIycMLi NUjLNG52TE2VTx?= NHfXVIhl\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> M3i2fFI2PDJ4NUS4
HCT116  MVfGeY5kfGmxbjDBd5NigQ>? M4jpXlExKML3TR?= M2KwUVI1KGh? NUjzT4Qz[2G3c3XzJIEheDV|LXTldIVv\GWwdDD0[ZRz[XCub3nkJGcyNWG{cnXzeEBqdiCmaYDsc4llKEiFVEGxOkBkdG:wZYOgSFMh[W6mIFS4 M4P4T|I2OzhyMEW1
MCF-10CA1a MlLuSpVv[3Srb36gRZN{[Xl? MVWxNOKh|ryP NYCwfY9mPDhiaB?= NEfSSXlFVVOR M2DPZ4lvcGmkaYTzJIJie2GuIHnueoF{cW:wIHHu[EBz\WS3Y3XkJHRITi4QskOtbY5lfWOnZDDpcpZie2mxbjD0c{Bj[XOjbDDs[ZZmdHN? M1rZOlI2OjV5N{K5
MCF-10A1  NI\5SWhHfW6ldHnvckBCe3OjeR?= NVjlSoR1OTEEoN88US=> NE\GNHQzPC92ODDo MYTEUXNQ NITKUIFqdmirYnn0d{BucWe{YYTpc44hd2Zibn;ycYFtKGK{ZXHzeEBmeGm2aHXsbYFtyqB? MlnjNlUzPTd5Mkm=
MCF-10CA1a NFniTJVHfW6ldHnvckBCe3OjeR?= NVrvSGR4OTEEoN88US=> MlHtNlQhcA>? M4TmcWROW09? Mon3[IVkemWjc3XzJJRp\SCWR1[t{tI{NWmwZIXj[YQhdVKQQTDs[ZZmdHNib3\NUXAzNMLiTV3QPUwh[W6mwrDpcpRm\3KrbtMg{tLDqDN? MYWyOVI2Pzd{OR?=
MCF-10CA1a NEjpb|VHfW6ldHnvckBCe3OjeR?= NGLHXHQyOMLizszN M3vYOFI1KGh? MUDEUXNQ M4fRXIlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MViyOVI2Pzd{OR?=
SK-BR-7 Mk[xSpVv[3Srb36gRZN{[Xl? NF63O2YyOMLizszN NGGxc|IzPCCq NWXDcJJ4TE2VTx?= NU\sOJVWcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u MX[yOVI2Pzd{OR?=
SUM102PT M3PvcGZ2dmO2aX;uJGF{e2G7 MlrINVDDqM7:TR?= M1zvWFI1KGh? MWXEUXNQ Ml32bY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NEC4NYMzPTJ3N{eyPS=>
RAW 264.7 MVjGeY5kfGmxbjDBd5NigQ>? NIizfIkyOMLizszN MnPxN|AhdWmw M{\scZBz\X[nboTzJJRp\SCyNUOgdoVlfWO2aX;uJIlvKHKnc4DvcpNmKHSxIFzQVy=> NWjLPWx7OjVzN{K1OFc>
RAW 264.7 NF7NVmtHfW6ldHnvckBCe3OjeR?= M4P4UlExyqEQvF2= Mof3N|AhdWmw M2fjPZJm\HWlZYOgeIhmKEySUz3heYdu\W62ZXSgeIhmKE6ILd86RkBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdIm= MWWyOVE4OjV2Nx?=
RAW 264.7 MWfGeY5kfGmxbjDBd5NigQ>? M4DuOFExyqEQvF2= NEH3W4Y{OCCvaX6= M2DqT4lvcGmkaYTzJGxRWy2rbnT1Z4VlKE6RIIDyc4R2[3Srb39CpC=> MXWyOVE4OjV2Nx?=
MCF7  MlLCR4VtdCCYaXHibYxqfHliQYPzZZk> MXeyMlUhyrWP MY[1JIQ> MVvEUXNQ NV\icG5we2Wwc3n0bZpmeyCPQ1[3JJRwKFCDUmCgbY5pcWKrdHnvci=> M4HjRlI2ODh3OUCy
MCF7  M{\hXmZ2dmO2aX;uJGF{e2G7 NGDUOogzNjViwsXN M4roSFQ5KGh? NVzRfY9mTE2VTx?= MV\k[YNz\WG|ZYOgeIhmKGixbX;sc4dwfXNiRGPCJJJmeGGrcjDmdoVyfWWwY3nldy=> M3jPO|I2ODh3OUCy
ACHN MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUWwMlUuOTBizszN MlXWNE03KGR? MmPiSG1UVw>? MnLTbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mli0NlUxPjd5OEe=
Caki-2 NIfic2RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Ml3aNE42NTFyIN88US=> NUKzOWF6OC14IHS= MYjEUXNQ MYrpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{noN|I2ODZ5N{i3
A498 M1nvVWNmdGxiVnnhZoltcXS7IFHzd4F6 NUfpPYhFOC53LUGwJO69VQ>? M3\FTFAuPiCm NF\welNFVVOR MXHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlroNlUxPjd5OEe=
115 M1O2cmNmdGxiVnnhZoltcXS7IFHzd4F6 MlrhNE42NTFyIN88US=> MUCwMVYh\A>? MXzEUXNQ NVjVcGZGcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVmyOVA3Pzd6Nx?=
117 M3;hW2NmdGxiVnnhZoltcXS7IFHzd4F6 M2Hw[|AvPS1zMDFOwG0> NEPxR|kxNTZiZB?= MYDEUXNQ NVq3OXB[cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MV:yOVA3Pzd6Nx?=
ACHN NIKzTIFHfW6ldHnvckBCe3OjeR?= MUGwMlUwOS93IN88US=> MVW0PEBp Mm\YSG1UVw>? MlG3cIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? M2TsRVI2ODZ5N{i3
Caki-2 M{Dt[WZ2dmO2aX;uJGF{e2G7 MYiwMlUwOS93IN88US=> NWLLTnJ5PDhiaB?= NUj6eVVWTE2VTx?= M3f2Roxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NF3BbG8zPTB4N{e4Oy=>
A498 MlXNSpVv[3Srb36gRZN{[Xl? M3;NO|AvPS9zL{Wg{txO NYHJfIlQPDhiaB?= MkOySG1UVw>? NF\1dlFt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= MUCyOVA3Pzd6Nx?=
115 NVnWTlFETnWwY4Tpc44hSXO|YYm= MX[wMlUwOS93IN88US=> Mof5OFghcA>? NHXKXHFFVVOR MUDs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? NXHaVYw6OjVyNke3PFc>
ACHN NVHTfVI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX2OUDPxE1? Ml;nOFghcA>? NU\TO2Z6TE2VTx?= MmLsbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg Moi3NlUxPjd5OEe=
Caki-2 NGPzS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV21JO69VQ>? NFu2co81QCCq NWXCdYdnTE2VTx?= NYnOW29OcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh MknwNlUxPjd5OEe=
A498 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXUeHI2KM7:TR?= NHHHbJA1QCCq MUfEUXNQ MWfpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= M2PielI2ODZ5N{i3
115 M3LSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HFflUh|ryP NYLHd5NDPDhiaB?= MXzEUXNQ MnT6bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg M3y1c|I2ODZ5N{i3
ACHN MUHGeY5kfGmxbjDBd5NigQ>? MmXvOUDPxE1? MU[0PEBp MWnEUXNQ NUXFd5JtcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> MXmyOVA3Pzd6Nx?=
Caki-2 NWLITFhWTnWwY4Tpc44hSXO|YYm= MVO1JO69VQ>? M1fFSlQ5KGh? M2\OcGROW09? M4nMPIlv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NV\HfHE2OjVyNke3PFc>
A498 M2\wSWZ2dmO2aX;uJGF{e2G7 M1fZflUh|ryP NGm4W3c1QCCq M2XWNWROW09? NVe3UJBicW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> MlTQNlUxPjd5OEe=
115 MVLGeY5kfGmxbjDBd5NigQ>? M{THPVUh|ryP NGK1XmU1QCCq M1i4d2ROW09? M2e1PIlv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= M121elI2ODZ5N{i3
MOLM-13 NHLFZ2NHfW6ldHnvckBCe3OjeR?= NUDrS2tkPsLizszN NVLO[IlmOC16IHi= NV;B[pBUTE2VTx?= M4\SWYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIC1N{whVUSPMjygdFIyKGGwZDDhZ4V1gWyjdHXkJJA2Ow>? M2HsRVI1QDh3MEiy
MOLM-13 M2G3UmZ2dmO2aX;uJGF{e2G7 M3P6RlbDqM7:TR?= NHvGfWw3KGh? Mm\rSG1UVw>? M{PQSIVvcGGwY3XzJJRp\SCjY3X0fYxifGmxbjDv[kBpcXO2b37lJGgzSiCjbnSgbIVifCC|aH;jb{Bxem:2ZXnud{BJe3B{NzDhcoQhUHOyOUC= MXuyOFg5PTB6Mh?=
HepG2 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYSzNYRCPzJiaB?= MYHEUXNQ MkDkTWM2OD1|NT64OkDDuSB{Lkmg{txO NECyV5kzPDh6NEiwPS=>
HepG2/As MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;pO|IhcA>? NU\zU5N[TE2VTx?= NUfM[nFFUUN3ME22PE4yOyEEsTC5MlYh|ryP NGT3eoszPDh6NEiwPS=>
SMMC7721 M1\mWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[xO|IhcA>? NIXzPHJFVVOR MXjJR|UxRTNzLkK4JOKyKDRwMjFOwG0> Mle2NlQ5QDR6MEm=
SMMC7721/Ac Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe3NkBp M2\IXmROW09? NXjKPHRsUUN3ME21OU4zOSEEsTC1MlA{KM7:TR?= NH7XXYozPDh6NEiwPS=>
Huh-7 NE\wTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:3NkBp M2S2SWROW09? M3jy[mlEPTB;M{OuPVYhyrFiMz65JO69VQ>? M2fmfVI1QDh2OEC5
Hep3B MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWW3NkBp MXHEUXNQ MkjITWM2OD1{MD6xPEDDuSBzLki0JO69VQ>? NFnUdJMzPDh6NEiwPS=>
HepG2 MonwRZBweHSxc3nzJGF{e2G7 M13TdYlv\HWlZYOgZZBweHSxc3nz MoLyNlQ5QDR6MEm=
SMMC7721 M4XFXGFxd3C2b4Ppd{BCe3OjeR?= NHvwOoJqdmS3Y3XzJIFxd3C2b4Ppdy=> NYTwPZVbOjR6OES4NFk>
Huh-7 NV\jOFhjSXCxcITvd4l{KEG|c3H5 M4HWVYlv\HWlZYOgZZBweHSxc3nz M2Hl[VI1QDh2OEC5
Hep3B M1:4XGFxd3C2b4Ppd{BCe3OjeR?= MlG3bY5lfWOnczDhdI9xfG:|aYO= MXqyOFg5PDhyOR?=
U2OS  MUfGeY5kfGmxbjDBd5NigQ>? NVToVIxvOjBizszN MUeyOEBp NUP4OFBTcW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQlPMNmEyNCCEQ1zYUOKh[W6mQlPMWy=> MnrONlQ5Pjd{NUm=
AML2 M3HJUGFxd3C2b4Ppd{BCe3OjeR?= NEHKeI8zNzFyIN88US=> M3H0bVI1NzR6IHi= M2LHR4lv\HWlZYOgZZBweHSxc3nz MVqyOFY2QTd2OR?=
MOML13 MWHBdI9xfG:|aYOgRZN{[Xl? NED5d2MzNzFyIN88US=> M3:yTVI1NzR6IHi= NIrLbHNqdmS3Y3XzJIFxd3C2b4Ppdy=> M2TNRlI1PjV7N{S5
AML2 M2fLeWZ2dmO2aX;uJGF{e2G7 M{fGVlEx|ryP MnziNk81KGh? MUDpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= M1fY[VI1PjV7N{S5
AML3 MYfGeY5kfGmxbjDBd5NigQ>? NWrFTFVNOTEQvF2= NF7JdmszNzRiaB?= MUTpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= NH3oS4wzPDZ3OUe0PS=>
MOML13 Mlz4SpVv[3Srb36gRZN{[Xl? MkX4NVDPxE1? NUC4eYJbOi92IHi= MUPpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= NVzCN4RiOjR4NUm3OFk>
BeWo M1XuXWZ2dmO2aX;uJGF{e2G7 MXezNEDDvU1? MnzrNlQhcA>? MX7pcoNz\WG|ZYOgdFU{NCCPZH2yMEBxOjFiYX7kJHB2dWFiYYSgeIhmKHC{b4TlbY4hdGW4ZXy= MVmyOFQ6QDF3NB?=
BeWo M2ThO2Fxd3C2b4Ppd{BCe3OjeR?= NEPLcHg{OCEEtV2= NVztPGZrOjRiaB?= NEXNWo5qdmO{ZXHz[ZMh[XCxcITvd4l{ NHju[nYzPDR7OEG1OC=>
OCI MVrGeY5kfGmxbjDBd5NigQ>? NU\kXGJzOTBizszN NUezSHpTOjRiaB?= NWrDbVB7fXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u NG\h[XEzPDR5M{W2Ni=>
MOLM NXrkNFVpTnWwY4Tpc44hSXO|YYm= MV:xNEDPxE1? NXe2VZQ{OjRiaB?= MoXheZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w M1HJPVI1PDd|NU[y
U2OS  MVjGeY5kfGmxbjDBd5NigQ>? M1LhW|IxKM7:TR?= MonQNlQhcA>? NUnh[FFxcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= NWfK[4NzOjR|Nk[wNFc>
RKO NYrUSINyTnWwY4Tpc44hSXO|YYm= NW[5V2Z{OjBizszN MlnpNlQhcA>? MmCzbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG|IITo[UBxPTNicILveIVqdg>? NEXZUYgzPDN4NkCwOy=>
U2OS  NEXhW3NHfW6ldHnvckBCe3OjeR?= M17q[|IxKM7:TR?= M2XtdVI1KGh? MkHubY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= MlfaNlQ{PjZyMEe=
RKO NXjSRYcyTnWwY4Tpc44hSXO|YYm= NWXTNFBIOjBizszN MYeyOEBp MmCwbY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= M4rzTFI1OzZ4MEC3
SMMC-7721  NEPt[HlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M131WlEvOjVvMkCg{txO NEHQZ3gzPC92OD:3NkBp M1rH[GROW09? NHHXbmZqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MXeyOFI5PjNzMh?=
HuH-7 MoHOR4VtdCCYaXHibYxqfHliQYPzZZk> MlnyNU4zPS1{MDFOwG0> Mnm5NlQwPDhxN{KgbC=> NWDHW|MyTE2VTx?= NUXRUmNVcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MmeyNlQzQDZ|MUK=
SMMC-7721  MXHBdI9xfG:|aYOgRZN{[Xl? M2mzcFIxKM7:TR?= NHf4OW41QCCq NWfkT4FzTE2VTx?= M4joWolv\HWlZYOgZZBweHSxc3nz M12xPVI1Ojh4M{Gy
HuH-7 NF72OXZCeG:ydH;zbZMhSXO|YYm= NXjSU3RmOjBizszN MlLCOFghcA>? MlLBSG1UVw>? NWPt[VVNcW6mdXPld{BieG:ydH;zbZM> MU[yOFI5PjNzMh?=
SMMC-7721  MVPGeY5kfGmxbjDBd5NigQ>? NX\rWY1nOTBizszN MV6zOkBp NYDZbI9vTE2VTx?= NGXBWnpld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>? NFLkfZMzPDJ6NkOxNi=>
HuH-7 NIj3UWNHfW6ldHnvckBCe3OjeR?= NWfWWHk2OTBizszN MnrQN|YhcA>? NFW5c|NFVVOR M3rPV4Rwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ MUmyOFI5PjNzMh?=
AT2 M37iXWZ2dmO2aX;uJGF{e2G7 NILiOGM2NzFyIN88US=> MWLs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? NE[5NXAzPDJ2MEKwNy=>
REH NXPxT4cxTnWwY4Tpc44hSXO|YYm= MmjXOU8yOCEQvF2= MVrs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? MmDqNlQzPDB{MEO=
UoCB6 M37hb2Z2dmO2aX;uJGF{e2G7 M1fNW|UwOTBizszN NFfleZdt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= M{DPfFI1OjRyMkCz
AT2 NVmxTpJmS2WubDDWbYFjcWyrdImgRZN{[Xl? MmDJNE0zPSEQvF2= Ml:zbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MmjSNlQzPDB{MEO=
REH MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3zSelAuOjVizszN MmPxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NF2xN3UzPDJ2MEKwNy=>
UoCB6 MofJR4VtdCCYaXHibYxqfHliQYPzZZk> M3jlfVAuOjVizszN MmrtbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M{nnXVI1OjRyMkCz
A2780 MmHKSpVv[3Srb36gRZN{[Xl? MVm1M|ExNzJyIN88US=> NVzEXoFuOjRiaB?= NF61ToV2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= M2TDcVI1OTN4MUS3
H460 MmD5SpVv[3Srb36gRZN{[Xl? MmC0OU8yOC9{MDFOwG0> NGLWe|YzPCCq NYK3boExfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= MYqyOFE{PjF2Nx?=
Lovo  NUX0XnZITnWwY4Tpc44hSXO|YYm= MlT6OU8yOC9{MDFOwG0> MknqNlQhcA>? MV71dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? MWWyOFE{PjF2Nx?=
A2780 M4TLT2Fxd3C2b4Ppd{BCe3OjeR?= M1XEeVUwOTBxMkCg{txO NG\hWXgzPCCq MYTlcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> MmC1NlQyOzZzNEe=
H460 NHjtd|BCeG:ydH;zbZMhSXO|YYm= MU[1M|ExNzJyIN88US=> NF3JR3czPCCq Mons[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> MmT0NlQyOzZzNEe=
Lovo  NE\EZ3dCeG:ydH;zbZMhSXO|YYm= M4LB[FUwOTBxMkCg{txO MWKyOEBp NF\WUohmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? M37STFI1OTN4MUS3

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID